S

Sanofi

Global pharma company; vaccines and R&D

Go-to-Market Capabilities Field Force Effectiveness Business Partner Manager - Dupixent

Full-TimeUpdated on 10/14/2026Deadline 11/1/26
No salary listed
Senior
Bachelor's, Master's, MBA, PhD
Shanghai, China
In Person
Sales & Account ManagementSales Operations

About the job

Requirements
  • A minimum bachelor's degree is required.
  • At least 6–8 years of experience in field force effectiveness, preferably in multinational pharmaceutical companies.
  • Solid knowledge of field force effectiveness tools, processes, and analytical frameworks, and an in-depth understanding of field team operations in the China pharmaceutical industry.
  • Project management skills and cross-functional communication skills are required.
  • Strong capability in Excel modeling and PowerPoint presentation is required.
  • Ability to solve difficult and changing situations and influence senior management.
  • Ability to self-challenge and challenge others constructively.
  • Good command of written English and verbal English communication is required.
  • Strong influence skills are required.
  • Strong analytical skills to conduct comprehensive analysis and provide business recommendations are required.
  • Strong communication and interpersonal skills, including the ability to interpret cross-functional dynamics, are required.
  • Ability to work under pressure to deliver high-quality analysis and operational work is required.
  • A high level of integrity and transparency is required.
Responsibilities
  • Lead development and execution of Dupixent-specific field force effectiveness strategy aligned with brand objectives and market dynamics.
  • Drive annual field force planning cycles, including resource forecasting, capacity planning, and strategic resource allocation.
  • Partner with brand marketing and commercial leadership to translate business strategy into actionable field force effectiveness roadmaps.
  • Conduct scenario planning and sensitivity analysis to support strategic decision-making.
  • Monitor the competitive landscape and market trends to inform field force effectiveness strategic recommendations.
  • Champion adoption and implementation of artificial-intelligence-powered tools and analytics to enhance field force productivity and effectiveness.
  • Identify opportunities for automation and intelligent decision-making across field force effectiveness processes.
  • Collaborate with Digital and Data Science teams to pilot and scale artificial intelligence solutions, such as predictive targeting and intelligent territory design.
  • Drive change management and capability building to support adoption of artificial-intelligence-enabled tools.
  • Design, develop, and maintain analytical tools and models for field force sizing and resource allocation.
  • Build dynamic simulation models to evaluate resource allocation scenarios and trade-offs.
  • Refine tools based on business feedback and changing market conditions.
  • Establish and enforce governance frameworks for territory alignment and target-setting processes.
  • Lead target hospital management, target customer management and segmentation, territory alignment and optimization, and objective setting and allocation.
  • Provide methodologies, templates, tools, and analytical support to ensure process compliance and quality.
  • Conduct quality assurance reviews and implement continuous improvement mechanisms.
  • Communicate with business-unit field force leaders, marketing teams, and go-to-market capabilities counterparts to support smooth execution.
  • Perform advanced data processing and analysis to generate actionable insights from complex datasets.
  • Apply best practices across business units and industry benchmarks to align analytical frameworks.
  • Provide routine and ad hoc analysis for business units and management, focusing on automation and self-service analytics.
  • Supervise field force effectiveness projects such as customer segmentation, territory optimization, and new product introduction.
  • Manage business-unit daily operational support, including headcount management and full-time-equivalent planning, field force performance tracking and identification of low performers, and data support requested by the business-unit management team.
Desired Qualifications
  • An advanced degree, such as a master's degree, PhD, or MBA, is preferred.
  • Experience in field force effectiveness at a multinational pharmaceutical company is preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)